Interferon Alpha (IFNA) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interferon Alpha (IFNA) – Pipeline Review, H2 2016’, provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interferon Alpha (IFNA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA)

The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Argos Therapeutics Inc

Neovacs SA

PsiOxus Therapeutics Ltd

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interferon Alpha (IFNA) Overview 6

Therapeutics Development 7

Interferon Alpha (IFNA) - Products under Development by Stage of Development 7

Interferon Alpha (IFNA) - Products under Development by Therapy Area 8

Interferon Alpha (IFNA) - Products under Development by Indication 9

Interferon Alpha (IFNA) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interferon Alpha (IFNA) - Products under Development by Companies 12

Interferon Alpha (IFNA) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interferon Alpha (IFNA) - Companies Involved in Therapeutics Development 21

Argos Therapeutics Inc 21

Neovacs SA 22

PsiOxus Therapeutics Ltd 23

ZIOPHARM Oncology Inc 24

Interferon Alpha (IFNA) - Drug Profiles 25

AGS-009 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

NG-345 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

RTS-IFN Alpha - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Interferon Alpha (IFNA) - Dormant Projects 34

Interferon Alpha (IFNA) - Discontinued Products 35

Interferon Alpha (IFNA) - Featured News & Press Releases 36

Dec 07, 2016: Neovacs obtains FDA "Fast Track" designation for IFNa Kinoid in Lupus (SLE) 36

Nov 23, 2016: 3P Biopharmaceuticals signs production partnership with Neovacs 36

Nov 07, 2016: Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus 37

Oct 12, 2016: Neovacs signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris 37

Apr 28, 2016: Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States 38

Apr 14, 2016: Neovacs obtains South Korea health authority approval for IND application with IFNa kinoid in Lupus 38

Jan 06, 2016: Neovacs Secures €5 Million, from the Public Funding Program to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kinoïd 39

Sep 24, 2015: Neovacs initiates phase IIb trial of IFNa-Kinoid for the treatment of lupus 39

Sep 17, 2015: Stellar Biotechnologies' Partner Neovacs Reports Potent and Long-Lasting Biological Activity of IFN-Alpha-Kinoid Immunotherapy 4 Years After Patient Dosing in Lupus Phase I/IIa Trial 40

Sep 09, 2015: Neovacs confirms potent and long-lasting biological activity of IFNa-Kinoid 4 years after patient dosing in phase I/IIa trial 40

Sep 01, 2015: Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus 41

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 42

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 43

May 13, 2015: Neovacs granted

1.8 million euros in research tax credit 44

Apr 01, 2015: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Argos Therapeutics Inc, H2 2016 21

Pipeline by Neovacs SA, H2 2016 22

Pipeline by PsiOxus Therapeutics Ltd, H2 2016 23

Pipeline by ZIOPHARM Oncology Inc, H2 2016 24

Dormant Projects, H2 2016 34

Discontinued Products, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports